Fu-Chen Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fu-Chen Song has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hanzhi Lu
Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
1 shared publication - Lei Zhang
Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
1 shared publication - Liang-Rong Zhang
Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, shutcm.edu.cn
1 shared publication - Mei-Dong Zhu
Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, shutcm.edu.cn
1 shared publication - Min Gao
Yichuan Community Health Service Center, Putuo District, Shanghai, China
1 shared publication - Ni Zhong
Department of Vascular Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, shutcm.edu.cn
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e1841497
Orientin Mitigates High Glucose/Ox‐LDL–Triggered Endothelial Cell Injury and Atherosclerosis by Regulating MARCH8‐Mediated NLRP3 Inflammasome Activation
Endothelial cells under oxidative stress and inflammation are vital contributors to the progression of atherosclerosis. Although Orientin possesses antioxidant and anti‐inflammatory activities, the effects of Orientin on oxidized low‐density lipoprotein and high glucose (ox‐LDL/HG)–triggered endothelial cell injury and diabetes‐accelerated atherosclerosis remain unclear. ApoE −/− mice were administered streptozotocin (STZ), fed with high‐fat diet (HFD), and then treated with Orientin to test the efficacy of Orientin on ameliorating atherosclerosis through pathological and biochemical assays. Human aortic endothelial cells (HAECs) were stimulated by ox‐LDL/HG followed by Orientin treatment, and the effects of Orientin on regulating HAEC viability, oxidative stress, inflammation, and endothelial‐mesenchymal transition (EndMT) were assessed using cell counting kit‐8 (CCK‐8), fluorescein diacetate (FDA) staining, quantitative real‐time PCR, immunofluorescence (IF), and western blot assays. The results showed that Orientin treatment decreased atherosclerotic plaque burden, lipid lesion, and collagen content in aortic and femoral arteries in diabetic mice. Meanwhile, Orientin alleviated hypercholesterolemia, as evidenced by decreased levels of total cholesterol, LDL‐cholesterol, and triglyceride. In HAECs, Orientin treatment increased cell viability and decreased inflammation, oxidative stress, and EndMT induced by ox‐LDL/HG. Furthermore, Orientin significantly inhibited reactive oxygen species (ROS)–triggered NOD‐like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis, as suggested by cleavage of caspase‐1 and gasdermin‐D (GSDMD), generation of interleukin (IL)‐18 and IL‐1β, and lactate dehydrogenase (LDH) release. Mechanistically, Orientin increased E3 ubiquitin ligase membrane‐associated RING‐CH 8 (MARCH8) expression in HAECs and resulted in subsequent MARCH8‐mediated ubiquitination and proteasomal degradation of the NLRP3 protein. Taken together, these data demonstrate that Orientin, which alleviates HAEC inflammation and pyroptosis through regulating the MARCH8/NLRP3 axis, might be a potential candidate for treating diabetes‐accelerated atherosclerosis.
- 1 January 2026
- Published by Wiley in Mediators of Inflammation
- Vol. 2026 (1) , e1841497
Open AccessOrientin Mitigates High Glucose/Ox‐LDL–Triggered Endothelial Cell Injury and Atherosclerosis by Regulating MARCH8‐Mediated NLRP3 Inflammasome Activation
Endothelial cells under oxidative stress and inflammation are vital contributors to the progression of atherosclerosis. Although Orientin possesses antioxidant and anti‐inflammatory activities, the effects of Orientin on oxidized low‐density lipoprotein and high glucose (ox‐LDL/HG)–triggered endothelial cell injury and diabetes‐accelerated atherosclerosis remain unclear. ApoE −/− mice were administered streptozotocin (STZ), fed with high‐fat diet (HFD), and then treated with Orientin to test the efficacy of Orientin on ameliorating atherosclerosis through pathological and biochemical assays. Human aortic endothelial cells (HAECs) were stimulated by ox‐LDL/HG followed by Orientin treatment, and the effects of Orientin on regulating HAEC viability, oxidative stress, inflammation, and endothelial‐mesenchymal transition (EndMT) were assessed using cell counting kit‐8 (CCK‐8), fluorescein diacetate (FDA) staining, quantitative real‐time PCR, immunofluorescence (IF), and western blot assays. The results showed that Orientin treatment decreased atherosclerotic plaque burden, lipid lesion, and collagen content in aortic and femoral arteries in diabetic mice. Meanwhile, Orientin alleviated hypercholesterolemia, as evidenced by decreased levels of total cholesterol, LDL‐cholesterol, and triglyceride. In HAECs, Orientin treatment increased cell viability and decreased inflammation, oxidative stress, and EndMT induced by ox‐LDL/HG. Furthermore, Orientin significantly inhibited reactive oxygen species (ROS)–triggered NOD‐like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and pyroptosis, as suggested by cleavage of caspase‐1 and gasdermin‐D (GSDMD), generation of interleukin (IL)‐18 and IL‐1β, and lactate dehydrogenase (LDH) release. Mechanistically, Orientin increased E3 ubiquitin ligase membrane‐associated RING‐CH 8 (MARCH8) expression in HAECs and resulted in subsequent MARCH8‐mediated ubiquitination and proteasomal degradation of the NLRP3 protein. Taken together, these data demonstrate that Orientin, which alleviates HAEC inflammation and pyroptosis through regulating the MARCH8/NLRP3 axis, might be a potential candidate for treating diabetes‐accelerated atherosclerosis.